TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15096406

Group type: EXPERIMENTAL
Intervention: Rasagiline, 2 mg/d for 1 year
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Rasagiline, 1 mg/d for 1 year
Number of subjects: 404

Group type: COMPARATOR
Intervention: Placebo for 6 months followed by rasagiline, 2 mg/d for 6 months
Number of subjects: 404
Study: 11549204

Group type: EXPERIMENTAL
Intervention: Imidapril 10 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Bisoprolol 5 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nilvadipine 8 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 12.5 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Imidapril 10 mg combined with Nilvadipine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Imidapril 10 mg combined with Hydrochlorothiazide
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Imidapril 10 mg combined with Bisoprolol
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Imidapril 10 mg combined with Hydrochlorothiazide, Bisoprolol, or Nilvadipine
Number of subjects: 16
Study: 9041068

Group type: EXPERIMENTAL
Intervention: Rehabilitation group (R)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Hospital-treatment group (H)
Number of subjects: 228
Study: 8177681

Group type: EXPERIMENTAL
Intervention: Picture
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Printed Word, Picture + Spoken Word
Number of subjects: 289

Group type: COMPARATOR
Intervention: Spoken Word, Printed Word
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Cluster index score
Number of subjects: 289
Study: 3123115

Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 49

Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 49
Study: 29987375

Group type: EXPERIMENTAL
Intervention: Endoscopic third ventriculostomy (ETV)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Shunt
Number of subjects: 158
Study: 25917562

Group type: EXPERIMENTAL
Intervention: High satisfaction with neighborhood
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Low satisfaction with neighborhood
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Neighborhood poverty
Number of subjects: 409
Study: 25675063

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine 5 mL (Group A)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine 4.5 mL + 20 mg of triamcinolone 0.5 mL (Group B)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine 4 mL + 40 mg of triamcinolone 1 mL (Group C)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 32
Study: 22961576

Group type: EXPERIMENTAL
Intervention: LOGIC-Insulin algorithm-guided glycemic control (LOGIC-C)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Nurse-directed glycemic control (Nurse-C)
Number of subjects: 300
Study: 20491750

Group type: EXPERIMENTAL
Intervention: Paracetamol 4 g/day for 5 days
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study: 18440447

Group type: EXPERIMENTAL
Intervention: Methylnaltrexone 1mg
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Methylnaltrexone >or=5mg
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Methylnaltrexone (all doses)
Number of subjects: 33
Study: 16554517

Group type: EXPERIMENTAL
Intervention: Running
Number of subjects: 32

Group type: COMPARATOR
Intervention: Walking
Number of subjects: 32
Study: 12618276

Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg per day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 10887384

Group type: EXPERIMENTAL
Intervention: Current cigarette smokers (S)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Non-smokers (NS)
Number of subjects: 22
Study: 8756362

Group type: EXPERIMENTAL
Intervention: High dose preoperative radiation ( > or = 45 Gray [Gy]) followed by surgical resection (Group A)
Number of subjects: 297

Group type: COMPARATOR
Intervention: Selective postoperative radiation (45‐50 Gy) after initial curative surgery (Group B)
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Preoperative radiation (Group A)
Number of subjects: 297

Group type: COMPARATOR
Intervention: Postoperative radiation (Group B)
Number of subjects: 297
Study: 1574364

Group type: EXPERIMENTAL
Intervention: Forced to drink according to the hospital's nursing care plan
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control over fluid intake
Number of subjects: 74
Study: 3886564

Group type: EXPERIMENTAL
Intervention: Cefotiam 1 g b.i.d. for 7 to 14 days
Number of subjects: 82

Group type: COMPARATOR
Intervention: Cefamandole 1 g t.i.d. for 7 to 14 days
Number of subjects: 82
Study: 30569763

Group type: EXPERIMENTAL
Intervention: CKD‐11101 (biosimilar darbepoetin‐alfa)
Number of subjects: 0

Group type: COMPARATOR
Intervention: NESP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CKD‐11101
Number of subjects: 0
Study: 30376084

Group type: EXPERIMENTAL
Intervention: Oral polio vaccine (OPV) administered during national health week (NHW) to 1 child under 5 in vaccinated households.
Number of subjects: 466

Group type: COMPARATOR
Intervention: Control group (unvaccinated households).
Number of subjects: 466
Study: 27323337

Group type: EXPERIMENTAL
Intervention: Ranolazine (R) at a dose of 500 mg/bid
Number of subjects: 40

Group type: COMPARATOR
Intervention: Beta-blockers or calcium-channel blockers (control)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ranolazine (R)
Number of subjects: 40
Study: 24558028

Group type: EXPERIMENTAL
Intervention: Complex lymphedema therapy (CLT)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Graduated compression stockings (30-40 mmHg)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both therapies
Number of subjects: 31
Study: 22154315

Group type: EXPERIMENTAL
Intervention: ICD therapy in patients <75 years old
Number of subjects: 936

Group type: EXPERIMENTAL
Intervention: ICD therapy in patients ≥75 years old
Number of subjects: 936
Study: 20851872

Group type: EXPERIMENTAL
Intervention: Mild-to-moderate CKD
Number of subjects: 435
Study: 17594783

Group type: EXPERIMENTAL
Intervention: L-dopa therapy in patients with PD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patients with PD not receiving L-dopa
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patients without PD (control group)
Number of subjects: 0
Study: 16253062

Group type: EXPERIMENTAL
Intervention: Laparoscopic nephrectomy using the Ligasure system
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional laparoscopic radical nephrectomy
Number of subjects: 30
Study: 12153376

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Enoxaparin (1.5 mg/kg once a day)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 146
Study: 10076482

Group type: COMPARATOR
Intervention: Community-level intervention promoting consistent condom use and bleach use, involving role-model stories, distribution of condoms and bleach, and encouragement from community members.
Number of subjects: 15205

Group type: EXPERIMENTAL
Intervention: Exposure to the intervention (role-model stories, condoms, bleach).
Number of subjects: 15205
Study: 7671981

Group type: EXPERIMENTAL
Intervention: Asymptomatic occlusion
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Mild stroke
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Moderate stroke
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Watershed ischemia
Number of subjects: 61
Study: 2137345

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham TENS
Number of subjects: 0
Study: 7033157

Group type: EXPERIMENTAL
Intervention: Cefamandole 1 gm IM every 6 hrs for 8 doses and Tobramycin 1 mg/kg IM for 1 dose, starting 2 hrs prior to surgery
Number of subjects: 37

Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Cefamandole and Tobramycin
Number of subjects: 37
Study: 31551147

Group type: EXPERIMENTAL
Intervention: Gadobutrol
Number of subjects: 112

Group type: COMPARATOR
Intervention: Gd-DTPA
Number of subjects: 112
Study: 26615912

Group type: EXPERIMENTAL
Intervention: Calorie restriction and weight-reduction program with nutritional education every 2 weeks for 2 months
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Patients with 25-hydroxy vitamin D concentration <10 ng/ml
Number of subjects: 82
Study: 26117157

Group type: EXPERIMENTAL
Intervention: Lurasidone 120mg/d
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Lurasidone 160mg/d
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Lurasidone 40/80mg/d
Number of subjects: 231

Group type: COMPARATOR
Intervention: Quetiapine XR 200-800mg/d
Number of subjects: 231
Study: 23183541

Group type: EXPERIMENTAL
Intervention: Accelerated up-dosing regimen (0.1-0.3-0.5 ml in weekly intervals)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Conventional up-dosing regimen (0.05-0.1-0.2-0.3-0.4-0.5 ml in weekly intervals)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 146
Study: 21711202

Group type: EXPERIMENTAL
Intervention: Yoga Therapy program (YT)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Waitlist group (WL)
Number of subjects: 18
Study: 19628124

Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 20078

Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 20078
Study: 16922792

Group type: EXPERIMENTAL
Intervention: Amphotericin-B-lipid-complex (ABLC) prophylaxis, 4 mg/kg, twice weekly starting on day +30 for patients on prednisone ≥30 mg/day.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fluconazole or itraconazole (200-400 mg/day) during neutropenic episode, continued for patients on lower steroid doses.
Number of subjects: 100
Study: 15195060

Group type: EXPERIMENTAL
Intervention: CIP/DEX (ciprofloxacin/dexamethasone otic suspension) 4 drops twice daily for 7 days
Number of subjects: 599

Group type: COMPARATOR
Intervention: OFL (ofloxacin otic solution) 5 drops twice daily for 10 days
Number of subjects: 599
Study: 11435269

Group type: EXPERIMENTAL
Intervention: Standard plus family intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard intervention
Number of subjects: 0
Study: 9723629

Group type: EXPERIMENTAL
Intervention: Fixed minidose warfarin (1.25 mg/day)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Standard adjusted-dose warfarin (INR between 2.0 and 3.0)
Number of subjects: 303
Study: 8210254

Group type: EXPERIMENTAL
Intervention: CPT-11 (irinotecan hydrochloride) administered as 100 mg/m2 weekly intravenous infusion or 150 mg/m2 fortnightly
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CPT-11 (irinotecan hydrochloride)
Number of subjects: 60
Study: 2691484

Group type: EXPERIMENTAL
Intervention: Amoxycillin/clavulanate iv (single prophylactic dose)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Control (no antibiotic)
Number of subjects: 181
Study: 5313064

Group type: EXPERIMENTAL
Intervention: Pyrimethamine 2 mg with sulfadoxine 40 mg, fortnightly
Number of subjects: 38

Group type: COMPARATOR
Intervention: Pyrimethamine alone at the recommended dose
Number of subjects: 38
Study: 30945074

Group type: EXPERIMENTAL
Intervention: Pendulum exercise
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 200
Study: 29228000

Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum ECGC 13110402 (2x10^9 CFU twice daily)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 25929604

Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Tacrolimus (TAC)
Number of subjects: 140
Study: 24362611

Group type: EXPERIMENTAL
Intervention: Mailed printed educational materials followed by mailed feedback
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Small group training followed by feedback
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Small group training only
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention (Control group)
Number of subjects: 0
Study: 21270121

Group type: EXPERIMENTAL
Intervention: Adjuvanted vaccines (Pandemrix, Focetria, FluvalP)
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Non-adjuvanted vaccines (Celvapan)
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Pandemrix (adjuvanted)
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: FluvalP (adjuvanted)
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Focetria (adjuvanted)
Number of subjects: 575

Group type: COMPARATOR
Intervention: Overall IBD flare risk after vaccination
Number of subjects: 575
Study: 19944317

Group type: EXPERIMENTAL
Intervention: Edaravone (30 mg intravenously infused just before reperfusion)
Number of subjects: 45
Study: 16704696

Group type: EXPERIMENTAL
Intervention: Frequency-doubling technology (FDT)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Tendency-oriented perimetry (TOP)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: SITA Standard (SS)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: SITA Fast (SF)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Criterion 2 for FDT
Number of subjects: 117
Study: 15195724

Group type: EXPERIMENTAL
Intervention: Dyract Seal (polyacid-modified resin composite based fissure sealant)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Delton FS+ (resin based fluoride fissure sealant)
Number of subjects: 53
Study: 11290435

Group type: EXPERIMENTAL
Intervention: Capecitabine (Xeloda)
Number of subjects: 602

Group type: COMPARATOR
Intervention: 5-fluorouracil plus leucovorin (5-FU/LV)
Number of subjects: 602
Study: 9249209

Group type: EXPERIMENTAL
Intervention: i.v. chloramphenicol 30 mg/kg
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: i.m. chloramphenicol 30 mg/kg
Number of subjects: 29

Group type: COMPARATOR
Intervention: i.v. chloramphenicol
Number of subjects: 29

Group type: COMPARATOR
Intervention: i.m. chloramphenicol
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: i.v. and i.m. chloramphenicol
Number of subjects: 29
Study: 8497817

Group type: EXPERIMENTAL
Intervention: Frusemide (33.2 mg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 11
Study: 3122515

Group type: EXPERIMENTAL
Intervention: Norgestrel-releasing IUCD
Number of subjects: 140

Group type: COMPARATOR
Intervention: Copper releasing IUCD
Number of subjects: 140
Study: 29898702

Group type: EXPERIMENTAL
Intervention: Breezhaler®
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Ellipta®
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: HandiHaler®
Number of subjects: 97
Study: 28571034

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) initiated at 1 month after surgery
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group with DBS initiated at 3 months after surgery
Number of subjects: 64
Study: 25703647

Group type: EXPERIMENTAL
Intervention: Topical application of ACT1 (alpha connexin carboxy-terminal)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (SOC) without ACT1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical application of ACT1
Number of subjects: 0
Study: 23392368

Group type: EXPERIMENTAL
Intervention: Zinc levels
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Selenium levels
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Prolactin levels
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Lymphopenia associated with zinc levels
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Selenium and prolactin concentrations
Number of subjects: 293
Study: 21443516

Group type: EXPERIMENTAL
Intervention: NVP 400 mg QD
Number of subjects: 126

Group type: COMPARATOR
Intervention: NVP 200 mg BID
Number of subjects: 126
Study: 18502299

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Multiple daily insulin injections (MDI)
Number of subjects: 382

Group type: COMPARATOR
Intervention: Oral hypoglycaemic agents
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: CSII
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: MDI
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: CSII and MDI
Number of subjects: 382
Study: 17052555

Group type: EXPERIMENTAL
Intervention: Ultrasonographically guided catheterization
Number of subjects: 130

Group type: COMPARATOR
Intervention: Landmark technique
Number of subjects: 130
Study: 14516342

Group type: COMPARATOR
Intervention: VVIR pacing mode
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: DDDR pacing mode
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Preimplant history of hypertension
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Preimplant history of supraventricular tachyarrhythmias
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: AF development
Number of subjects: 407
Study: 10647968

Group type: EXPERIMENTAL
Intervention: FFLTC program
Number of subjects: 68

Group type: COMPARATOR
Intervention: Seated ROM program
Number of subjects: 68
Study: 8680886

Group type: EXPERIMENTAL
Intervention: Acemannan (400 mg orally four times daily)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Acemannan
Number of subjects: 63
Study: 1880218

Group type: EXPERIMENTAL
Intervention: Spirapril 12 mg to 48 mg once daily
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 7040186

Group type: EXPERIMENTAL
Intervention: Betahistine dihydrochloride (3 X 8 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (3 X 25 mg)
Number of subjects: 32
Study: 31466882

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Health Education (HE)
Number of subjects: 204
Study: 30907291

Group type: EXPERIMENTAL
Intervention: EG1 (psychoeducation about PMDD)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: EG2 (stereotypic PMDD-information)
Number of subjects: 216

Group type: COMPARATOR
Intervention: CG (information unrelated to PMDD)
Number of subjects: 216
Study: 30321272

Group type: EXPERIMENTAL
Intervention: 400 mg capsule containing 100 mg seaweed (poly)phenol and 300 mg maltodextrin
Number of subjects: 80

Group type: COMPARATOR
Intervention: 400 mg maltodextrin placebo control capsule
Number of subjects: 80
Study: 26968850

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation and cognitive behavioral therapy (CBT) intervention
Number of subjects: 35

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 35
Study: 24272224

Group type: EXPERIMENTAL
Intervention: 80-kV/370-mAs
Number of subjects: 30

Group type: COMPARATOR
Intervention: 100-kV/300-mAs
Number of subjects: 30
Study: 21769512

Group type: EXPERIMENTAL
Intervention: Resident Assessment Instrument (RAI) training and support from the research team for 13 months
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (no RAI training)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Resident Assessment Instrument (RAI) training
Number of subjects: 69
Study: 20674774

Group type: COMPARATOR
Intervention: Usual care (Arm 1)
Number of subjects: 4675

Group type: EXPERIMENTAL
Intervention: Automated support (Arm 2)
Number of subjects: 4675

Group type: EXPERIMENTAL
Intervention: Automated and assisted support (Arm 3)
Number of subjects: 4675

Group type: EXPERIMENTAL
Intervention: Automated, assisted, and care management support (Arm 4)
Number of subjects: 4675

Group type: COMPARATOR
Intervention: Usual care (for patients with positive FOBT or adenomas)
Number of subjects: 4675

Group type: EXPERIMENTAL
Intervention: Nurse care management (for patients with positive FOBT or adenomas)
Number of subjects: 4675
Study: 17509067

Group type: EXPERIMENTAL
Intervention: pioglitazone
Number of subjects: 34

Group type: COMPARATOR
Intervention: voglibose
Number of subjects: 34
Study: 11034037

Group type: EXPERIMENTAL
Intervention: Usual medical care with input from a clinical pharmacist
Number of subjects: 1054

Group type: COMPARATOR
Intervention: Usual medical care
Number of subjects: 1054
Study: 9312196

Group type: EXPERIMENTAL
Intervention: Intermittent slow-release sodium fluoride (SRNaF, 25 mg B.I.D.) plus calcium citrate (400 mg Ca B.I.D.)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo plus calcium citrate (400 mg Ca B.I.D.)
Number of subjects: 75
Study: 8369129

Group type: EXPERIMENTAL
Intervention: ondansetron
Number of subjects: 100

Group type: COMPARATOR
Intervention: customary treatments
Number of subjects: 100
Study: 3749390

Group type: EXPERIMENTAL
Intervention: Intravenous diazepam (0.15 mg/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31738192

Group type: EXPERIMENTAL
Intervention: Telephone-delivered exercise therapy (n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: In-person delivered exercise therapy (n = 10)
Number of subjects: 20
Study: 29237228

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Both MTX and AZA
Number of subjects: 35
Study: 26370061

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) 50,000 U administered 30 min prior to CA
Number of subjects: 138

Group type: COMPARATOR
Intervention: Normal saline and n-acetyl cysteine before CA
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Cystatin C (CC)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Neutrophil-gelatinase-associated-lipocalin (NGAL)
Number of subjects: 138
Study: 25466429

Group type: EXPERIMENTAL
Intervention: Levocetirizine (5 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Fexofenadine (60 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 23586514

Group type: EXPERIMENTAL
Intervention: Pulverized lanthanum carbonate (LC) chewable preparation
Number of subjects: 41

Group type: COMPARATOR
Intervention: Other patients (not NC group)
Number of subjects: 41
Study: 20525842

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) treatment for 6 months
Number of subjects: 563
Study: 18513259

Group type: EXPERIMENTAL
Intervention: Rizatriptan
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 16635791

Group type: EXPERIMENTAL
Intervention: ATG (Thymoglobulin)
Number of subjects: 0
Study: 14529098

Group type: EXPERIMENTAL
Intervention: HFA-albuterol delivered via Autohaler (1, 2, or 4 puffs)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: HFA-albuterol delivered via P&B (1 or 2 puffs)
Number of subjects: 39

Group type: COMPARATOR
Intervention: HFA-placebo Autohaler (2 puffs)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Both active inhalers (Autohaler and P&B)
Number of subjects: 39